At the beginning of 1997, about 890,000 leprosy patients were registered for chemotherapy, globally. The World Health Organisation estimates that the true prevalence of patients in need of chemotherapy is about 1,150,000 patients. This estimate was reached through information provided by national programme managers from endemic countries, taking into account registered figures, health service coverage and MDT implementation. This means that there would presently be a gap of about 260,000 undetected patients. This is an approximate figure, since population surveys conducted in different areas often showed that there were two to three times more patients than reported through the registered figures.
BT - ILEP Technical Bulletin C2 -UK
C5 -
C7 -
CY - London LA - eng M1 - 11 M3 - e-publication N2 -
At the beginning of 1997, about 890,000 leprosy patients were registered for chemotherapy, globally. The World Health Organisation estimates that the true prevalence of patients in need of chemotherapy is about 1,150,000 patients. This estimate was reached through information provided by national programme managers from endemic countries, taking into account registered figures, health service coverage and MDT implementation. This means that there would presently be a gap of about 260,000 undetected patients. This is an approximate figure, since population surveys conducted in different areas often showed that there were two to three times more patients than reported through the registered figures.
PB - International Federation of Anti-Leprosy Associations PP - London PY - 1997 EP - 4 p. T2 - ILEP Technical Bulletin TI - ILEP Technical Bulletin 11 : Detecting hard to reach leprosy patients ER -